中国医疗集团(08225.HK)将负责利托那韦口服液上市前後临床研究推广和治疗
中国医疗集团(08225.HK)公布,迈可欣(利托那韦口服液)复产注册於今年2月14日获得批准(首家),利托那韦为抗病毒蛋白(酉每)抑制剂,且洛匹那韦/利托那韦为国家卫健委针对新型肺炎的国家版诊疗方案推荐用药。
集团指,旗下新型冠状病毒肺炎临床特别专案研究组,中国科学院武汉病毒研究所等也发现迈可欣对新型冠状病毒(COVID19)有抑制作用。集团将负责迈可欣的上市前後「临床研究推广和治疗」。
同时,由集团组织的关於瑞德西韦 Remdesivir(RNA 聚合(酉每)抑制剂)新药研究申报和拓展性同情用药,也收到国家药监局的再次积极回复和交流。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.